ClinicalTrials.gg
RecruitingNCT05756023Updated Oct 19, 2023

IVF\ICSI Outcome in Women With Polycystic Ovary Syndrome

An interventional study of the pregnancy rate at IVF / ICSI cycles in PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Egymedicalpedia · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 104 studies in Polycystic Ovary Syndrome with a site in Egypt — 16 open to participants now, 18 under way, 1 of them phase 3. Polycystic Ovary Syndrome · Egypt.

Planned enrollment
24th of 83
156 · median 100
Started
2023
with 11 others
No phase
44 of 104
12 open now
Primary completion
2026-12
later than 12 of 17 live
Registered
59th of 104
by date
Lead sponsor
3 of 104
Egymedicalpedia

Among the 104 studies in Polycystic Ovary Syndrome with a site in Egypt, this one is the 24th largest by planned enrollment of the 83 interventional ones that give a count, is one of 12 that started in 2023, is one of 44 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 59th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

16 of the 104 studies in Polycystic Ovary Syndrome with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Polycystic Ovary Syndrome with a site in Egypt, or all of them as a file.
02

Study summary

Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .

Read the detailed description

Sub-fertile women with PCOS will usually benefit from conventional treatments, such as lifestyle changes, ovulation induction, or laparoscopic ovarian drilling, but some will ultimately need assisted reproductive techniques, either if they will need or if they wish, such as controlled ovarian hyperstimulation and IVF.

In these cases, controlled ovarian hyperstimulation is closely related to high drug costs, need for daily injections and frequent monitoring, whereas it sometimes results in an increased rate of cycle cancellations and potential life threatening complications due to ovarian hyperstimulation syndrome and in the retrieval of immature oocytes, leading to poor fertilization and lower cleavage, pregnancy, and live birth rates compared to the conventional IVF cycles ,although this has not been confirmed by other studies .

In addition, ovulation induction is associated with a high risk of multiple pregnancies due to multiple follicular development, so that it has to be individualized and closely monitored.

In-vitro fertilization (IVF) is a common therapeutic modality used in infertile women. IVF has different success rates in different subgroups of patients.

It is necessary to alter the common standard protocols to overcome the potential obstacles in some populations of patients and achieve the best results . Obesity with PCOS status of patient may decrease the fertilization rate and clinical pregnancy chance after IVF (probably by decreasing the oocyte count and increasing the gonadotropin resistance); however, the results of different studies are conflicting

03

Conditions studied

  • PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Oligo-ovulation or anovulation.
  • Clinical and/or biochemical hyper androgenesim.
  • Polycystic ovaries.

Exclusion criteria

Exclusion Criteria:

  1. Androgen-secreting tumors (ovarian or adrenal).
  2. Adult-onset congenital adrenal hyperplasia.
  3. Thyroid diseases.
  4. Cushing's syndrome.
  5. Diabetes Mellitus.
  6. recurrent ICSI failure
  7. endocrine, hematologic and disorders
  8. Non chromosomal and genetic abnormalities
  9. Major uterine anomalies, bad surgical history, sever endometriosis, , hydrosalpinx, uterine fibroids
  10. Azospermia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
156 participants (estimated)

Study arms

  • Active comparator
    PCOs Patients

    To compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs

    Procedure: the pregnancy rate at IVF / ICSI cycles

  • Active comparator
    Non PCOs Patients

    To compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs

    Procedure: the pregnancy rate at IVF / ICSI cycles

Interventions

  • Procedurethe pregnancy rate at IVF / ICSI cycles

    To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS

06

What researchers measure

Primary outcomes

  1. pregnancy rate

    To compare the pregnancy rate at IVF / ICSI cycles between women with PCOS and non PCOS women

    Time frame: From baseline to 15 days after the embryo transfere day.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 219 interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 15, 2026
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05756023
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Jun 1, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 19, 2023

Study contacts

Islam Mahfouz, MSC
Contact
islam.ibrahim@med.aun.edu.eg
01118434861
Momen Kamel, Professor
study chair · Assiut University, Faculty of medicine, Assuit.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion